BXPHF Stock - Botanix Pharmaceuticals Limited
Unlock GoAI Insights for BXPHF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.76M | $2.07M | $3.77M | $2.75M | $6.89M |
| Gross Profit | $2.32M | $-1,582,711 | $-3,045,931 | $-7,537,672 | $315,799 |
| Gross Margin | 40.3% | -76.5% | -80.7% | -273.6% | 4.6% |
| Operating Income | $-86,342,852 | $-15,459,646 | $-13,612,432 | $-22,447,282 | $-9,446,677 |
| Net Income | $-86,396,186 | $-13,869,709 | $-9,153,974 | $-13,170,749 | $-3,334,000 |
| Net Margin | -1500.6% | -670.2% | -242.7% | -478.1% | -48.4% |
| EPS | $-0.05 | $-0.01 | $-0.01 | $-0.01 | $-0.00 |
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.
Visit WebsiteEarnings History & Surprises
BXPHFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | — | — | — | — |
Q2 2025 | Apr 24, 2025 | $0.00 | $-0.01 | -1796.8% | ✗ MISS |
Q3 2024 | Aug 30, 2024 | — | $-0.00 | — | — |
Q2 2024 | Apr 30, 2024 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.00 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q4 2020 | Dec 30, 2020 | — | $0.00 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.01 | — | — |
Q4 2019 | Dec 30, 2019 | — | $-0.01 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.01 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.00 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.01 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.00 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.01 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.00 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.00 | — | — |
Q4 2015 | Dec 30, 2015 | — | $-0.00 | — | — |
Latest News
Frequently Asked Questions about BXPHF
What is BXPHF's current stock price?
What is the analyst price target for BXPHF?
What sector is Botanix Pharmaceuticals Limited in?
What is BXPHF's market cap?
Does BXPHF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BXPHF for comparison